Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Metastatic disease involving the stomach is an unusual and difficult clinical problem. A review of 1010 autopsies of patients with cancer disclosed 17 cases of gastric metastases (an incidence of 1.7%), with breast cancer, lung cancer, and melanoma being the most frequent primaries. The clinical manifestations of epigastric pain, melena, and anemia are nonspecific, necessitating radiographic examination of the gastrointestinal tract. The radiographic findings are usually sufficient to suggest the diagnosis.
 ...
PMID:Metastatic disease involving the stomach. 119 Jan 98

A human malignant melanoma cell strain, UCLA-SO-M14 (M14), was adapted to grow in serum-free, chemically defined medium (CDM). The 3 M KCl extract prepared from the CDM-grown cells (M-14-CDM) was assayed against leukocytes from melanoma patients, patients with other cancers, and normal donors by leukocyte migration inhibition (LMI). The leukocytes from 15 to 27 (56%) melanoma patients tested were LMI positive. In contrast, 4 of 18 (22%) other cancer patients and 5 of 30 (17%) normal donors leukocytes were LMI positive. One of 14 melanoma patients' leukocytes were LMI positive for a control 3 M KCI extract from autologous muscle. Comparative studies were performed with the M14-CDM extract and a 3 M KCI extract from a freshly biopsied tumor specimen from the donor of the M14 cell strain. Seven of 12 (58%) melanoma patients' leukocytes were LMI positive to the M14-CDM extract, but only 2 of 12 (17%) were LMI positive to the autologous melanoma tissue extract. Furthermore, only 100 to 300 mug protein of M14-CDM extract were required to educe delayed cutaneous hypersensitivity response in 6 of 8 (75%) melanoma patients and 0 of 5 lung cancer patients, but 500 mug protein from biopsied autologous melanoma tissue extract were needed to produce delayed cutaneous hypersensitivity response in 24 of 42 (57%) melanoma patients and 7 of 28 (25%) nonmelanoma cancer patients. These data suggest: (a) the M14-CDM cells synthesized melanoma-associated antigen(s) (MAA) in CDM; (B) the 3 M KCI extraction procedure effectively removed the MAA from the M14-CDM cells; (c) the M14-CDM cells were a more potent source of MAA than the surgical autologous melanoma specimen; and (d) the M14-CDM cells provided a continuous source of standard MAA.
 ...
PMID:Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium. 126 Jul 67

The aim of this work was to develop a computer program (CANEST) to estimate the risk of cancer in patient populations and to use this program to investigate cancer risk associated with several dermatological disorders. Patients seen at the dermatology departments at the Karolinska Hospital and South Hospital were used for the study of chronic urticaria, condylomata acuminata, basal cell carcinoma, lichen planus and positive patch tests. The national Swedish In-Patient Register was used to find all patients hospitalized for dermatomyositis or polymyositis since 1964. From eleven large dermatological centers in Sweden, details of close to 5,000 PUVA-treated patients were obtained for study. The computer program CANEST was developed and used to calculate the expected number of malignant tumors in these patient populations, based on incidence data from the Swedish Cancer Register for the years 1958-1987. By matching the patients' records with the Cancer Register the actual number of cancers was obtained. Of 1,155 patients with chronic urticaria, a malignancy was diagnosed in 36, while the expected number was 41: clearly there is therefore no association between chronic urticaria and malignancy. In 3,260 patients with condylomata acuminata there was no increased risk of cancer in situ of the cervix (relative risk = 1.5; 95% confidence interval 0.9 to 2.5) and the number of genitourinary cancers in males was almost three times higher than expected (2.6; 1.2 to 5.0). These results indicate that the risk of developing cervical carcinoma in situ is less than previously thought, but the implications of the increase in genitourinary tumors in males are uncertain. Patients with basal cell carcinoma had an increased risk of malignancy in general. Melanoma risk was seven times greater in males (6.6; 3.0 to 12.5) after the basal cell carcinoma diagnosis. Risks of squamous cell carcinoma of the skin, lung cancer, thyroid cancer and cancer of the uterine cervix were also increased. No increased risk of cutaneous malignancy was found in 2,071 patients with lichen planus, but for oral cancer it was six times greater in males (5.9; 2.5 to 11.4). A slight general increase in malignancy risk was found in 2,183 males (1.3; 1.1 to 1.5) with positive patch tests, but not in 3,675 females. When individual sites were analyzed, cancers of the lung, larynx, uterine cervix and prostate were significantly increased. The implications of this are uncertain, but might indicate a common failure of the immune system which might predispose for both conditions, or be a marker of certain occupational exposure.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Skin disease and malignancy. An epidemiological study. 128 38

The occurrence of ERBB-2 (HER-2/NEU) oncogene amplification was studied in 203 DNA samples obtained from 175 cancer patients. Amplification of ERBB-2 oncogene was established in 14 out of 63 (22%) patients with breast cancer, 1 out of 23 cases of ovarian tumor, 1 out of 19 cases of large bowel cancer and 1 out of 27 patients with cancer of the thyroid. Patients with lung cancer (34), soft tissue sarcoma (6) and malignant melanoma (3) failed to reveal any changes in the above oncogene. A tendency was established for ERBB-2 oncogene amplification to be associated with lymph node involvement in female patients with breast cancer: amplification was observed in 9 out of 28 patients presenting with lymph node metastases and only in 5 out of 29 metastases-free cases. To summarize, ERBB-2 oncogene is fairly often activated in human tumors but a high occurrence of the gene amplification was observed in female patients with breast cancer only.
 ...
PMID:[The search for amplification of the ERBB-2 oncogene in human tumors]. 130 Jul 65

In a multicentre study patients with liver metastases stratified to the histology of the primary tumour were investigated. A total of 102 patients with colorectal adenocarcinoma, non-small-cell lung cancer, pancreatic cancer, primary liver carcinoma and malignant melanoma were treated with the thioether lipid ilmofosine. The drug was administered orally as a tablet at a dosage of 150-300 mg/day (75 mg/tablet). The tolerability of ilmofosine was poor. There was a dose-limiting gastrointestinal toxicity with nausea, vomiting and loss of appetite (WHO grade II-IV) in 67% of patients. During the period of therapy (1-29 weeks, 8.5 weeks mean) no complete remission and no partial response were observed. We thus conclude that treatment with oral ilmofosine is not effective in patients with liver metastases due to various malignancies.
 ...
PMID:Treatment results of the thioether lipid ilmofosine in patients with malignant tumours. 132 33

Three patients with primary lung cancer had perirenal metastases detected with CT. In two cases a symptomatic perirenal mass was the first evidence of metastatic spread and CT-guided biopsy of the perirenal lesion confirmed the diagnosis of metastatic lung cancer. The perirenal space is an unusual but potentially significant site of metastasis from lung cancer as well as other tumors such as malignant melanoma. It is suggested that connections between perirenal and intrathoracic lymphatics are the most probable mechanism of this pattern of spread by lung cancers.
 ...
PMID:Perirenal metastases from lung cancer: CT diagnosis. 132 Nov 75

The role of combination chemotherapy in the treatment of advanced non-small-cell lung cancer is controversial. At best, a small survival benefit can be achieved. Therefore, other treatment modalities are needed. On the basis of the promising treatment results with interleukin-2 (IL-2) -containing immunotherapy in renal cell cancer and melanoma, we performed a phase I-II study with IL-2 and interferon alpha (IFN-alpha). Eligible patients were treated with IL-2 18 x 10(6) IU/m2/day by continuous intravenous infusion (c.i.v.) for 3 days. On the same days, 5 x 10(6) U/m2/day IFN-alpha was given intramuscularly. After a rest period of 4 days, patients at the first dose level received IL-2 2.4 x 10(6) IU/m2/day c.i.v. for a period of 28 days, followed by 14 days' rest, 14 days' treatment, 7 days' rest, and a final treatment for 14 days. Patients at the second dose level were treated according to the same schedule, in which the dose of IL-2 was increased to 3.6 x 10(6) IU/m2/day. During low-dose IL-2 treatment, patients received IFN-alpha 5 x 10(6) U/m2/day on days 1 and 4 of each week. Eleven patients were admitted to the study, six at the first and five at the second dose level. Median age was 54 years; all patients had a performance status of 0 or 1. The most important adverse effects included anorexia, fatigue, nausea, and headache, which were not dose limiting. In the 11 patients treated, no responses were seen. Nine patients developed progressive disease during the first 5 weeks of treatment. We concluded that this regimen of IL-2 and IFN-alpha is ineffective.
 ...
PMID:Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. 132 67

The investigational antineoplastic agent, taxol, a natural product from the yew, Taxus sp. L., is currently being evaluated in a series of Phase II clinical trials. To date, the drug has shown activity against ovarian cancer, lung cancer, and melanoma. Taxol is a potent microtubule stabilizing agent that selectively blocks cells in the G2 and M phases of the cell cycle and is cytotoxic in a time-concentration dependent manner. It is well known from radiobiological principles that G2 and M are the most radiosensitive phases of the cell cycle. On the rationale that taxol could function as a cell-cycle selective radiosensitizer, we examined the consequences of combined drug-radiation exposures on the human grade 3 astrocytoma cell line, G18. Survival curve analysis shows a dramatic interaction between taxol and ionizing radiation with the degree of enhanced cell killing dependent on taxol concentration and on the fraction of cells in the G2 or M phases of the cell cycle. The sensitizer enhancement ratio (SER) for 10 nM taxol at 10% survival is approximately 1.8. These results obtained with cycling aerated radioresistant brain tumor cells indicate that significant advantage may derive from appropriate time-concentration dependent interactions in combined modality protocols.
 ...
PMID:Taxol: a novel radiation sensitizer. 134 33

Taxotere (RP 56976, NSC 628503) is a new semisynthetic analog of taxol (NSC 125973) with promising antitumor activity in a variety of preclinical screening systems. Clinical responses after treatment with taxol have been observed in ovarian cancer, breast, lung cancer and melanoma. Both agents act through induction of microtubule polymerization. We have studied and compared the antiproliferative action of Taxotere and taxol against a variety of freshly explanted human tumor specimens using an in vitro soft agar cloning system. Final concentrations of 0.025-10 micrograms/ml were used for both agents in short-term (1 h) or continuous (14 days) incubations. Taxotere was studied using a 1 h incubation in a total of 167 tumor specimens of which 85 (51%) were evaluable. At 10 micrograms/ml, Taxotere inhibited 32 out of 78 (41%) specimens (colony formation less than or equal to 0.5 x control). Cytotoxicity of Taxotere was observed against breast, lung, ovarian, colorectal cancer and melanoma tumor colony forming units. For comparison, 227 specimens were exposed to taxol for 1 h. At 10 micrograms/ml, 32 out of 97 evaluable specimens (33%) were significantly inhibited. Cytotoxicity was observed against breast, lung, ovarian, colorectal cancer and melanoma tumor colony forming units. In head-to-head comparisons, 29 specimens were found more sensitive to Taxotere than taxol, while only 13 were more sensitive to taxol than to Taxotere. These data indicate that cross-resistance between the two agents is incomplete and that on a concentration basis Taxotere is more cytotoxic than taxol in the majority of human primary tumor specimens evaluated.
 ...
PMID:Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. 135 30

In 1977, a Cancer Control and Surveillance Unit was established by the South Australian government. The infrastructure of the Unit was the State's Cancer Registry which was established simultaneously. By 1990, approximately 70,000 invasive cancer cases had been notified to the Registry for a population which had increased from 1,287,550 in 1977 to 1,400,000. In 1990, 2940 cancers were notified in males and 2640 in females. The leading sites in males were the prostate, lung, colon and melanoma of the skin, while in females they were the breast, colon, melanoma of the skin and lung. An increase in age-standardised incidence rates for all cancer sites combined has been documented for the 1977-1990 period. The magnitude of the increase was 7% in males and 12% in females. Meanwhile, there were 1544 male cancer deaths and 1203 female cancer deaths in 1990. Amongst males, age-standardised mortality rates tended to decline in the 1980's, due largely to a reducing age-standardised incidence of lung cancer. By comparison, an increased lung cancer incidence in females contributed to an overall increase of 6% in the age-standardised mortality rate for cancers of all sites combined in this sex during the life of the Registry. During the period 1977-1990 there was a 55% increase in the number of new invasive cancers in males and females combined. Most of this increase can be attributed to the ageing of the South Australian population and to a much lesser degree to population growth. During the same period there was a concomitant increase in 43% in the number of deaths where the underlying cause of death was cancer. Case survival rates are found to be very similar in South Australia to those reported for the United States, with about 51% of cases surviving their cancers 5 years after diagnosis. 5-year survival rates for the diagnostic period, 1983-1990, were generally better than for 1977-1982. The evidence for improved survival was strongest for cancers of the oesophagus, colon, cervix, prostate and testes, and for low-grade and medium-grade lymphomas and chronic myeloid leukaemias. When case survival rates were calculated for childhood tumours, significant improvements were found for acute lymphatic leukaemias and non-Hodgkin lymphomas for the diagnostic period, 1983-1990, when compared with 1977-1982.
 ...
PMID:The South Australian Cancer Registry: a means of assessing cancer incidence, mortality and case survival. 138 37


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>